These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
346 related articles for article (PubMed ID: 30858151)
1. Enhancing the antitumor functions of invariant natural killer T cells using a soluble CD1d-CD19 fusion protein. Das R; Guan P; Wiener SJ; Patel NP; Gohl TG; Evans E; Zauderer M; Nichols KE Blood Adv; 2019 Mar; 3(5):813-824. PubMed ID: 30858151 [TBL] [Abstract][Full Text] [Related]
2. CD1d-antibody fusion proteins target iNKT cells to the tumor and trigger long-term therapeutic responses. Corgnac S; Perret R; Derré L; Zhang L; Stirnemann K; Zauderer M; Speiser DE; Mach JP; Romero P; Donda A Cancer Immunol Immunother; 2013 Apr; 62(4):747-60. PubMed ID: 23242316 [TBL] [Abstract][Full Text] [Related]
3. Activated invariant natural killer T cells directly recognize leukemia cells in a CD1d-independent manner. Aoki T; Takami M; Takatani T; Motoyoshi K; Ishii A; Hara A; Toyoda T; Okada R; Hino M; Koyama-Nasu R; Kiuchi M; Hirahara K; Kimura MY; Nakayama T; Shimojo N; Motohashi S Cancer Sci; 2020 Jul; 111(7):2223-2233. PubMed ID: 32324315 [TBL] [Abstract][Full Text] [Related]
4. Enhanced Anti-lymphoma Activity of CAR19-iNKT Cells Underpinned by Dual CD19 and CD1d Targeting. Rotolo A; Caputo VS; Holubova M; Baxan N; Dubois O; Chaudhry MS; Xiao X; Goudevenou K; Pitcher DS; Petevi K; Kachramanoglou C; Iles S; Naresh K; Maher J; Karadimitris A Cancer Cell; 2018 Oct; 34(4):596-610.e11. PubMed ID: 30300581 [TBL] [Abstract][Full Text] [Related]
5. iNKT cell cytotoxic responses control T-lymphoma growth in vitro and in vivo . Bassiri H; Das R; Guan P; Barrett DM; Brennan PJ; Banerjee PP; Wiener SJ; Orange JS; Brenner MB; Grupp SA; Nichols KE Cancer Immunol Res; 2014 Jan; 2(1):59-69. PubMed ID: 24563871 [TBL] [Abstract][Full Text] [Related]